Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
CIG MEDIA GROUP, LP
Autores
D'ANDREA, David
SORIA, Francesco
ABUFARAJ, Mohammad
PONES, Mario
GONTERO, Paolo
MACHADO, Andre T.
ENIKEEV, Dmitry V.
GLYBOCHKO, Petr V.
Autor de Grupo de pesquisa
Citação
CLINICAL GENITOURINARY CANCER, v.18, n.1, p.20-+, 2020
Resumo
We compared the oncologic outcomes of patients treated with bacillus Calmette-Guerin (BCG)-Tice versus BCG-Moreau for non-muscle-invasive bladder cancer using inverse-probability survival analyses and found no significant difference in recurrence- and progression-free survival between strains. However, the use of maintenance cycles was significantly associated with improved recurrence- and progression-free survival. Prospective designed trials are required to confirm these findings in light of the BCG shortage. Background: The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guerin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). Materials and Methods: We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic centers. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and Cox proportional hazards regression analyses were used to compare recurrence-free (RFS) and progression-free survival (PFS) of patients in the 2 treatment groups. In addition, we performed exploratory analyses of treatment effect according to the receipt of adequate BCG treatment, high-risk disease, age, gender, smoking status, pathologic stage, and pathologic grade. Results: A total of 321 (48.6%) patients were treated with BCG-Tice and 339 (51.4%) with BCG-Moreau. IPTW-adjusted Cox proportional hazard regression analysis did not show a difference in RFS (hazard ratio, 0.88; 95% confidence interval, 0.56-1.38; P = .58) or PFS (hazard ratio, 0.55; 95% confidence interval, 0.25-1.21, P = .14) between BCG-Tice and BCG-Moreau. On subgroup analyses, we could not identify an association of BCG strain with outcomes. Conclusions: There was no difference in RFS and PFS between BCG-Tice and BCG-Moreau strains in the adjuvant treatment of NMIBC. However, we confirmed the importance of maintenance therapy for achieving a sustainable response in patients with intermediate- and high-risk NMIBC.
Palavras-chave
BCG, Progression, Recurrence, Response, Strain
Referências
- Abufaraj M, 2019, EUR UROL, V75, P649, DOI 10.1016/j.eururo.2018.11.052
- Abufaraj M, 2018, CURR OPIN UROL, V28, P570, DOI 10.1097/MOU.0000000000000544
- Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041
- Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2
- Brosch R, 2007, P NATL ACAD SCI USA, V104, P5596, DOI 10.1073/pnas.0700869104
- Byrne RA, 2001, J UROLOGY, V165, P1473, DOI 10.1016/S0022-5347(05)66330-6
- FELLOWS GJ, 1994, BRIT J UROL, V73, P639, DOI 10.1111/j.1464-410X.1994.tb07548.x
- Hall MC, 2007, J UROLOGY, V178, P2314, DOI 10.1016/j.juro.2007.09.003
- Inamoto T, 2013, UROL ANNALS, V5, P7, DOI 10.4103/0974-7796.106873
- Kamat AM, 2015, NAT REV UROL, V12, P225, DOI 10.1038/nrurol.2015.58
- Kamat AM, 2013, EUR UROL, V63, P4, DOI 10.1016/j.eururo.2012.09.057
- Karakiewicz PI, 2006, BJU INT, V97, P997, DOI 10.1111/j.1464-410X.2006.06036.x
- Lamm DL, 2000, J UROLOGY, V163, P1124, DOI 10.1016/S0022-5347(05)67707-5
- Leung AS, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-413
- Malmstrom PU, 2009, EUR UROL, V56, P247, DOI 10.1016/j.eururo.2009.04.038
- Mari A, 2019, BJU INT, V123, P11, DOI 10.1111/bju.14417
- Oddens J, 2013, EUR UROL, V63, P462, DOI 10.1016/j.eururo.2012.10.039
- Rentsch CA, 2014, EUR UROL, V66, P677, DOI 10.1016/j.eururo.2014.02.061
- Rink M, 2013, EUR UROL, V64, P624, DOI 10.1016/j.eururo.2013.07.007
- Rink M, 2012, EUR UROL, V61, P854, DOI 10.1016/j.eururo.2011.12.055
- Sengiku A, 2013, J UROLOGY, V190, P50, DOI 10.1016/j.juro.2013.01.084
- Shariat SF, 2003, UROLOGY, V61, P1140, DOI 10.1016/S0090-4295(03)00236-X
- Shariat SF, 2010, IMMUNOTHERAPY-UK, V2, P381, DOI [10.2217/imt.10.1, 10.2217/IMT.10.1]
- Shariat SF, 2009, UROL ONCOL-SEMIN ORI, V27, P653, DOI 10.1016/j.urolonc.2009.07.020
- Sylvester RJ, 2002, J UROLOGY, V168, P1964, DOI 10.1016/S0022-5347(05)64273-5
- VEGT PDJ, 1995, J UROLOGY, V153, P929, DOI 10.1016/S0022-5347(01)67606-7
- Witjes JA, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.05.033
- Witjes W P, 1996, Semin Urol Oncol, V14, P10